Grifols, S.A. GRFS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -13.37%
- 1 year
- -11.57%
- Open
- 8.10
- Prev close
- 8.04
- Mkt cap
- 5.51B
- Vol
- 803.38K
- Avg vol
- 530.76K
- EPS
- 0.77
- P/E
- 10.52
- Div yield
- 1.32%
More statistics
- Low
- 8.05
- High
- 8.25
- Forward P/E
- 6.08
- Beta
- 1.20
- Short ratio
- 11.06
- Inst. own
- 57.27%
- Dividend
- 0.11
- Ex-div date
- Jul 1, 2026
- Earnings
- Nov 2, 2026
- 50-d avg
- 7.59
- 200-d avg
- 8.00
- 1y target
- 10.37
2Y chart
Events in this range
- Jun 17, 2025Rating: JP Morgan · Neutral → Neutral
- Jul 29, 2025Earnings: 0.19; estimate 0.23; surprise -17.39%
- Aug 12, 2025Dividend: 0.17579
- Nov 4, 2025Earnings: 0.2108; estimate 0.2417; surprise -12.78%
- Dec 8, 2025Rating: JP Morgan · Neutral → Neutral
- Feb 26, 2026Earnings: 0.2891; estimate 0.29; surprise -0.31%
- May 7, 2026Earnings: 0.1731; estimate 0.1613; surprise 7.32%
- Jul 2, 2026Dividend: 0.10582
- Jul 28, 2026Earnings: 0.2512; estimate 0.27; surprise -6.96%
- Oct 26, 2026Rating: JP Morgan · Neutral → Neutral
Signals (87)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 4 days ago |
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| MACD: Sell Signal | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| RSI: Oversold | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 17, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 27, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 15, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| SMA: Bearish | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| SMA: Bearish | Nov 12, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 5, 2025 | 12 months ago |
| RSI: Oversold | Nov 5, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 21, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| SMA: Bearish | Sep 9, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 29, 2025 | 1 year ago |
| RSI: Overbought | Jul 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 24, 2025 | 1 year ago |
| RSI: Overbought | Jul 21, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 18, 2025 | 1 year ago |
| RSI: Overbought | Jun 16, 2025 | 1 year ago |
| RSI: Overbought | Jun 5, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 16, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 11, 2025 | 1 year ago |
| RSI: Overbought | Feb 28, 2025 | 1 year ago |
| SMA: Bullish | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Feb 14, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
Key statistics
- Market cap
- 5.51B
- Enterprise value
- 22.20B
- Trailing P/E
- 10.52
- Forward P/E
- 6.08
- PEG ratio
- 0.19
- Price / sales
- 0.74
- Price / book
- 1.77
- EPS (TTM)
- 0.77
- Beta
- 1.20
- Dividend yield
- 1.32%
- Payout ratio
- 37.97%
- Profit margin
- 6.09%
- Revenue (TTM)
- 7.42B
- Revenue growth
- -0.90%
- Free cash flow
- 572.92M
- Total cash
- 537.00M
- Total debt
- 9.36B
- Return on equity
- 6.93%
- Shares outstanding
- 258.22M
- Short % of float
- 0.00%
- 50-day average
- 7.59
- 200-day average
- 8.00
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 10.37
- Target (high)
- 11.73
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.30396.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 0.3202 | — | — | — |
| Jul 28, 2026 | Jun 30, 2026 | 0.27 | 0.2512 | -0.02 | -6.96% |
| May 7, 2026 | Mar 31, 2026 | 0.1613 | 0.1731 | +0.01 | +7.32% |
| Feb 26, 2026 | Dec 31, 2025 | 0.29 | 0.2891 | 0.00 | -0.31% |
| Nov 4, 2025 | Sep 30, 2025 | 0.2417 | 0.2108 | -0.03 | -12.78% |
| Jul 29, 2025 | Jun 30, 2025 | 0.23 | 0.19 | -0.04 | -17.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | JP Morgan | main | Neutral | Neutral |
| Dec 8, 2025 | JP Morgan | main | Neutral | Neutral |
| Jun 17, 2025 | JP Morgan | main | Neutral | Neutral |
| Mar 12, 2024 | Deutsche Bank | down | Hold | Sell |
| Dec 5, 2023 | JP Morgan | main | Neutral | Neutral |
| Nov 5, 2021 | Deutsche Bank | down | Buy | Hold |
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Spain
- Website
- grifols.com
News
- Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest
- Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
- Grifols says Canada plasma license suspension has no impact
- Grifols: Better Plasma Economics Can Unlock A Discounted Equity
- Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)
- GRFS or SDZNY: Which Is the Better Value Stock Right Now?
- Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
- Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
- Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on GRFS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Brandes Investment Partners L.P. | 14.47% | 37,816,285 | 306.31M | Jun 29, 2026 |
| Capital World Investors | 8.76% | 22,911,656 | 185.58M | Jun 29, 2026 |
| Permian Investment Partners, Lp | 7.55% | 19,740,679 | 159.90M | Jun 29, 2026 |
| Black Creek Investment Management Inc. | 2.94% | 7,682,055 | 62.22M | Jun 29, 2026 |
| Bank of America Corporation | 2.51% | 6,550,337 | 53.06M | Jun 29, 2026 |
| Millennium Management Llc | 1.67% | 4,369,934 | 35.40M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEW PERSPECTIVE FUND | 5.37% | 14,039,027 | 113.72M | Sep 29, 2026 |
| Intl Growth & Income Fd.-Intl Growth and Income Fd. | 1.98% | 5,180,416 | 41.96M | Sep 29, 2026 |
| Brandes Investment Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND | 1.84% | 4,803,459 | 38.91M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.69% | 1,812,126 | 14.68M | Sep 29, 2026 |
| Brandes Investment Trust-BRANDES SMALL CAP VALUE FUND | 0.63% | 1,647,438 | 13.34M | Jun 29, 2026 |
| 2023 ETF Series Trust-Brandes International ETF | 0.34% | 893,153 | 7.23M | Jun 29, 2026 |